OCA (Ocaliva®), the first-in-class FXR agonist, is approved by the FDA for non-cirrhotic primary biliary cholangitis (PBC) and is nearing approval for liver fibrosis due to NASH [48]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.